Mr. Greg Fenton reports
ZENTEK COMPLETES SHELF-LIFE EFFICACY TESTING FOR ZENGUARD ENHANCED AIR FILTER COMMERCIALIZATION
Shelf-life efficacy testing has been completed on Zentek Ltd.'s aged ZenGuard enhanced air filters, which is required for medical device compliance.
Highlights
- ZenGuard enhanced air filters were aged for 20 months prior to testing to establish the product's shelf life;
- Viral filtration efficiency (VFE) was unchanged after aging demonstrating that the ZenGuard coating has a consistent performance over a duration of 20 months.
ZenGuard enhanced air filters
On Nov. 27, 2024, Zentek announced that the company will manufacture and sell its ZenGuard enhanced air filters as a Class I medical device under its medical device establishment licence (MDEL). The change in regulatory pathway required the completion of "end product stability and performance testing." These tests are essential for medical devices as products must demonstrate consistent performance and safety of the device until a subsequent expiry date. The expiry date must be clearly identified on the label of all medical devices.
ZenGuard enhanced air filters were real time aged for 20 months and then submitted to LMS Technologies Inc. (LMS) for VFE and shedding testing. The VFE was tested for the aged filters to determine the reduction in bioaerosols that is achieved under normal operating conditions with an airflow of 500 feet/minute and was consistent with ASHRAE 241 Section L standards. The recently completed testing of the 20-month aged filters measured an initial VFE of 38.1 per cent which was similar to the original test performance of 37.7 per cent.
Likewise, a shedding test on the 20-month aged filters was completed using a laser particle counter to determine the number and size of particles in the airstream under normal operating conditions (500 ft/min airflow). The shedding test demonstrated that the coating maintains excellent adhesion to the substrate over 20 months as the number of particles counted in the airstream after passing through the filter were within statistical deviation with the background particle counts measured with no filter present in the test chamber.
Based on the VFE and shedding test results, ZenGuard enhanced air filters will be labelled with a 20-month expiry from the date of manufacture.
The company continues to prioritize the completion of all required documentation to support the manufacture and sale of ZenGuard enhanced air filters under its existing MDEL alongside ZenGuard surgical masks. This documentation will be completed in compliance with Canadian medical device regulations and ISO 13485:2016 quality management system for medical devices.
Greg Fenton, Zentek's chief executive officer, commented: "The pathway to commercialization for ZenGuard enhanced air filters has been a long journey and we are pleased to have finally completed all testing necessary required for a medical device. These recent results further demonstrate to users that ZenGuard enhanced air filters are an effective and safe solution to help reduce the transmission of infectious bioaerosols up to the expiry date. We look forward to providing further announcements as we move towards commercialization."
About Zentek Ltd.
Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the company's commercial partners a competitive advantage by making their products better, safer and greener.
Zentek's patented technology platform ZenGUARD is shown to have enhanced viral filtration efficiency for surgical masks and HVAC (heating, ventilation and air conditioning) systems. Zentek's ZenGUARD production facility is located in Guelph, Ont.
Zentek, through its wholly owned subsidiary, Triera Biosciences Ltd., has a global exclusive licence to the aptamer-based platform technology developed by McMaster University, which is being jointly developed by Zentek and McMaster for both the diagnostic and therapeutic markets.
We seek Safe Harbor.
© 2025 Canjex Publishing Ltd. All rights reserved.